
Michael Jf Hubank

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3784642/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. Journal of Clinical Investigation, 2008, 118, 3143-3150.	3.9	1,069
2	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. Cancer Discovery, 2018, 8, 1270-1285.	7.7	187
3	Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nature Communications, 2020, 11, 2662.	5.8	157
4	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	7.7	157
5	Sperm-Induced Modification of the Oviductal Gene Expression Profile After Natural Insemination in Mice1. Biology of Reproduction, 2004, 71, 60-65.	1.2	147
6	Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis and Rheumatism, 2007, 56, 1954-1965.	6.7	135
7	DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage. Nature, 1999, 400, 81-83.	13.7	132
8	Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene, 2007, 26, 6560-6565.	2.6	132
9	A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood, 2005, 105, 4484-4491.	0.6	129
10	Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nature Biotechnology, 2021, 39, 1115-1128.	9.4	126
11	Prox1 maintains muscle structure and growth in the developing heart. Development (Cambridge), 2009, 136, 495-505.	1.2	112
12	Effective Transplantation of Photoreceptor Precursor Cells Selected via Cell Surface Antigen Expression. Stem Cells, 2011, 29, 1391-1404.	1.4	107
13	[19] cDNA representational difference analysis: A sensitive and flexible method for identification of differentially expressed genes. Methods in Enzymology, 1999, 303, 325-349.	0.4	102
14	Ranked prediction of p53 targets using hidden variable dynamic modeling. Genome Biology, 2006, 7, R25.	13.9	102
15	Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. Journal of Clinical Oncology, 2021, 39, 2859-2871.	0.8	101
16	Discovery of genes with highly restricted expression patterns in theDrosophilawing disc using DNA oligonucleotide microarrays. Development (Cambridge), 2003, 130, 659-670.	1.2	98
17	Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood, 2004, 103, 291-300.	0.6	94
18	Maternal diet programs embryonic kidney gene expression. Physiological Genomics, 2005, 22, 48-56.	1.0	90

MICHAEL JF HUBANK

44

#	Article	IF	CITATIONS
19	Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression. Arthritis and Rheumatism, 2010, 62, 896-907.	6.7	71
20	Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. Clinical Cancer Research, 2020, 26, 608-622.	3.2	71
21	Subtype-Specific <i>FBXW7</i> Mutation and <i>MYCN</i> Copy Number Gain in Wilms' Tumor. Clinical Cancer Research, 2010, 16, 2036-2045.	3.2	69
22	K ATP Channel Gene Expression Is Induced by Urocortin and Mediates Its Cardioprotective Effect. Circulation, 2002, 106, 1556-1562.	1.6	66
23	Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1. Human Molecular Genetics, 2007, 16, 2122-2134.	1.4	61
24	From the top down: towards a predictive biology of signalling networks. Trends in Biotechnology, 2003, 21, 290-293.	4.9	58
25	STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage. Journal of Cell Science, 2005, 118, 1629-1639.	1.2	54
26	Genomic profile of advanced breast cancer in circulating tumour DNA. Nature Communications, 2021, 12, 2423.	5.8	54
27	Effects of ADMA upon Gene Expression: An Insight into the Pathophysiological Significance of Raised Plasma ADMA. PLoS Medicine, 2005, 2, e264.	3.9	52
28	Optimised ARID1A immunohistochemistry is an accurate predictor of <i>ARID1A</i> mutational status in gynaecological cancers. Journal of Pathology: Clinical Research, 2018, 4, 154-166.	1.3	51
29	Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium insensitive phospholipase A 2 gene expression. FASEB Journal, 2003, 17, 2313-2315.	0.2	49
30	Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype. Pharmacogenetics and Genomics, 2010, 20, 665-676.	0.7	49
31	Tnfaip8 is an essential gene for the regulation of glucocorticoid-mediated apoptosis of thymocytes. Cell Death and Differentiation, 2010, 17, 316-323.	5.0	49
32	Fitting ordinary differential equations to short time course data. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2008, 366, 519-544.	1.6	47
33	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. Clinical Chemistry, 2018, 64, 1626-1635.	1.5	46
34	Sterol O-Acyltransferase 1 (SOAT1, ACAT) Is a Novel Target of Steroidogenic Factor-1 (SF-1, NR5A1,) Tj ETQq0 C) 0 rgBT /O	overlock 10 Tf
35	Cardioprotection mediated by urocortin is dependent upon PKCÎu activation. FASEB lournal. 2005. 19. 1-18.	0.2	44

³⁶ A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. European Journal of Cancer, 2019, 121, 224-235. 1.3

MICHAEL JF HUBANK

#	Article	IF	CITATIONS
37	Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia. British Journal of Haematology, 2005, 130, 26-35.	1.2	39
38	Robustness of the p53 network and biological hackers. FEBS Letters, 2005, 579, 3037-3042.	1.3	38
39	New targets of urocortin-mediated cardioprotection. Journal of Molecular Endocrinology, 2010, 45, 69-85.	1.1	36
40	The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors. Leukemia, 2011, 25, 321-330.	3.3	36
41	Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. Cancer Discovery, 2021, 11, 92-107.	7.7	36
42	Radiation-induced delayed cell death in a hypomorphic Artemis cell line. Human Molecular Genetics, 2006, 15, 1303-1311.	1.4	35
43	Differential gene expression in the hippocampus of the Df1/+ mice: A model for 22q11.2 deletion syndrome and schizophrenia. Brain Research, 2007, 1139, 48-59.	1.1	33
44	Microarray analysis of the Df1 mouse model of the 22q11 deletion syndrome. Human Genetics, 2005, 116, 486-496.	1.8	27
45	ChIPâ€onâ€chip analysis reveals angiopoietin 2 (Ang2, ANGPT2) as a novel target of steroidogenic factorâ€1 (SFâ€1, NR5A1) in the human adrenal gland. FASEB Journal, 2011, 25, 1166-1175.	0.2	27
46	Telomere elongation through hTERT immortalization leads to chromosome repositioning in control cells and genomic instability in Hutchinsonâ€Gilford progeria syndrome fibroblasts, expressing a novel SUN1 isoform. Genes Chromosomes and Cancer, 2019, 58, 341-356.	1.5	27
47	Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients. Neuro-Oncology Advances, 2021, 3, vdab013.	0.4	27
48	The cardioprotective effect of urocortin during ischaemia/reperfusion involves the prevention of mitochondrial damage. Biochemical and Biophysical Research Communications, 2004, 321, 479-486.	1.0	26
49	Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i> -Mutant Diffuse Intrinsic Pontine Glioma. Cancer Discovery, 2022, 12, 416-431.	7.7	25
50	Microarray interrogation of human metanephric mesenchymal cells highlights potentially important molecules in vivo. Physiological Genomics, 2007, 28, 193-202.	1.0	24
51	Dissection of a complex transcriptional response using genomeâ€wide transcriptional modelling. Molecular Systems Biology, 2009, 5, 327.	3.2	22
52	Genome-Wide Analysis of Alternative Splicing in Medulloblastoma Identifies Splicing Patterns Characteristic of Normal Cerebellar Development. Cancer Research, 2011, 71, 2045-2055.	0.4	21
53	Gene expression profiling and its application in studies of haematological malignancy. British Journal of Haematology, 2004, 124, 577-594.	1.2	17
54	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. Oncotarget, 2017, 8, 112036-112050.	0.8	16

MICHAEL JF HUBANK

#	Article	IF	CITATIONS
55	Cardiovascular GO Annotation Initiative Year 1 Report: Why Cardiovascular GO?. Proteomics, 2008, 8, 1950-1953.	1.3	15
56	DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition. Cancer Discovery, 2022, 12, 712-729.	7.7	15
57	Analysis of Gene Transcription in Cells Lacking DNA-PK Activity. Radiation Research, 2001, 156, 167-176.	0.7	13
58	SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay. Wellcome Open Research, 2021, 6, 9.	0.9	13
59	Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk. Oncogene, 2008, 27, 2929-2933.	2.6	12
60	Microarray analysis of mitogenic effects of T3 on the rat liver. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1926-1933.	1.4	12
61	Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. European Journal of Cancer, 2022, 162, 209-220.	1.3	12
62	E4BP4 expression is regulated by the t(17;19)-associated oncoprotein E2A-HLF in pro-B cells. British Journal of Haematology, 2004, 125, 560-567.	1.2	9
63	Revealing Individual Signatures of Human T Cell CDR3 Sequence Repertoires with Kidera Factors. PLoS ONE, 2014, 9, e86986.	1.1	9
64	Expression of the excision repair gene, ERCC3 (excision repair cross-complementing), during mouse development. Developmental Brain Research, 1994, 81, 66-76.	2.1	8
65	Transcriptional changes in trichothiodystrophy cells. DNA Repair, 2008, 7, 1364-1371.	1.3	8
66	rHVDM: an R package to predict the activity and targets of a transcription factor. Bioinformatics, 2009, 25, 419-420.	1.8	8
67	Correction of scaling mismatches in oligonucleotide microarray data. BMC Bioinformatics, 2006, 7, 251.	1.2	7
68	rHVDM – a fast and user-friendly R package to predict transcription factor targets from microarray time series data. BMC Systems Biology, 2007, 1, .	3.0	4
69	Identification of a novel genetic locus associated with immune mediated thrombotic thrombocytopenic purpura. Haematologica, 2021, , .	1.7	2
70	Response of NOTCH1-Activated Tracheal Adenoid Cystic Carcinoma to the Gamma Secretase Inhibitor Nirogacestat. JCO Precision Oncology, 2021, 5, 1579-1583.	1.5	1
71	Genome-Wide Methylation Analysis of Patients with Diffuse Large B Cell Lymphoma Treated on the UK NCRI R-CHOP 14 Vs 21 Trial. Blood, 2016, 128, 1747-1747.	0.6	0
72	Comparison of Three Assays for Identification of IDH Mutations in AML. Blood, 2019, 134, 5195-5195.	0.6	0

#	Article	IF	CITATIONS
73	MODL-19. DIPG HARBOUR ALTERATIONS TARGETABLE BY MEK INHIBITORS, WITH ACQUIRED RESISTANCE MECHANISMS OVERCOME BY COMBINATORIAL UP- OR DOWN-STREAM INHIBITION. Neuro-Oncology, 2020, 22, iii414-iii414.	0.6	0
74	Targeted Next Generation Sequencing Improves Diagnosis in Unclassifiable Leukemic Indolent B-Cell Non-Hodgkin Lymphoma and Identifies a Subset with Recurrent MYD88 Mutations in a Prospective Multicentre Study. Blood, 2020, 136, 12-13.	0.6	0
75	EXTH-46. ARTIFICIAL INTELLIGENCE-BASED IDENTIFICATION OF COMBINED VANDETANIB AND EVEROLIMUS IN THE TREATMENT OF ACVR1-MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2020, 22, ii97-ii97.	0.6	Ο
76	DDRE-07. DIPG HARBOUR ALTERATIONS TARGETABLE BY MEK INHIBITORS, WITH ACQUIRED RESISTANCE MECHANISMS OVERCOME BY COMBINATORIAL INHIBITION. Neuro-Oncology, 2020, 22, ii62-ii62.	0.6	0
77	DIPG-41. Multi-omic profiling of patient-derived subclones identifies aggressive cellular subpopulations in paediatric diffuse high-grade gliomas (PDHGGs). Neuro-Oncology, 2022, 24, i27-i28.	0.6	0